Literature DB >> 29262899

[Icaritin Reverses Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ].

Zhi-Yuan Li1, Zhen-Jie Li2, Xu Chen3, Xing-Ru Huang3, Zhi-Qing Fang3, Jian-Guo Zhang3, Jian Fang4.   

Abstract

OBJECTIVE: To investigate the reversing effect of icaritin on multidrug resistance of multiple myeloma cell lines KM3/BTZ and its underlying mechanism.
METHODS: KM3/BTZ cells were established by a gradually ascending gradient induction of bortezomib (BTZ). The sensitivities of KM3 and KM3/BTZ cells to 7 chemotherapeutic drugs, the inhibition and reversal effects of icaritin on proliferation and drug-resistance of KM3/BTZ cells were analyzed by MTT. The apoptosis was analyzed by flow cytometry, and the expression of Par-4, HSP27 and P-gp were detected by Western blot.
RESULTS: KM3/BTZ cells were not only resistant to BTZ, but also to other 6 chemotherapeutic drugs. The resistance index (RI) to BTZ was 17.84, and higher than that of other chemotherapeutic drugs. Icaritin inhibited the proliferation and induced the apoptosis of KM3/BTZ cells. The IC50 value of BTZ decreased from 0.345 µg/ml to 0.149 µg/ml, and the reversal index was 2.38 (P<0.05). The expression of Par-4 protein increased in a concentration-dependent manner, while the expression of HSP27 and P-gp were down-regulated.
CONCLUSION: Icaritin can inhibit cell proliferation and induce apoptosis of KM3/BTZ cells, moreover, can effectively reverse the multidrug resistance of KM3/BTZ cells. The mechanism may be related with down-regulation of HSP27 and P-gp expression, and up-regulation of Par-4 expression.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29262899     DOI: 10.7534/j.issn.1009-2137.2017.06.020

Source DB:  PubMed          Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi        ISSN: 1009-2137


  1 in total

1.  Icaritin Inhibits Migration and Invasion of Human Ovarian Cancer Cells via the Akt/mTOR Signaling Pathway.

Authors:  Lvfen Gao; Yuan Ouyang; Ruobin Li; Xian Zhang; Xuesong Gao; Shaoqiang Lin; Xiaoyu Wang
Journal:  Front Oncol       Date:  2022-04-01       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.